{
  "docId": "019de071-dd7f-730a-8977-e46a36e30dcf",
  "docSlug": "abc22aebd2d55a5159142df321cabcee",
  "documentTitle": "Bionomics | IPO Presentation Deck | 38 slides",
  "authorId": "bionomics",
  "authorName": "Bionomics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7391304,
  "pageNumber": 22,
  "pageCount": 38,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a timeline-based visual to explain the clinical trial structure.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-dd7f-730a-8977-e46a36e30dcf/22",
  "deckHref": "/decks/019de071-dd7f-730a-8977-e46a36e30dcf",
  "deckJsonHref": "/decks/019de071-dd7f-730a-8977-e46a36e30dcf.json",
  "deckAnchorHref": "/decks/019de071-dd7f-730a-8977-e46a36e30dcf#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.22,
        "x": 0.75,
        "y": 0.12
      },
      "kind": "callout",
      "text": "PHASE 2B: Single potential registrational-supporting trial for monotherapy treatment in PTSD. KEY INCLUSION CRITERIA: Female and male (18 – 75 years), Current PTSD diagnosis, CAPS-5 ≥ 30 (Screening & Baseline) (& ≤ 25% decrease Screening to Baseline). ~25 Sites",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7eef4e97-778d-440a-a31f-966098235b84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.65,
        "x": 0.06,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "12-week outpatient BID dosing followed by follow-up",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "802f6498-becc-4e35-a1dc-11f85ed82eb2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.68,
        "x": 0.28,
        "y": 0.78
      },
      "kind": "list",
      "text": "Fast Track designation from FDA; Topline data expected 1H'23",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86475a1a-f8ec-48a8-b6f4-004ea8e806e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.06,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "Phase 2B 1:1 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED BNC210 MONOTHERAPY IN PTSD PATIENTS ~200 Subjects",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33702308-0bf8-419f-a813-1c4b1c2f63ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.25,
        "y": 0.6
      },
      "kind": "paragraph",
      "text": "SECONDARY ENDPOINTS: Various patient-reported symptoms of PTSD, changes in anxiety and depression symptoms, and global and social functioning; Safety & tolerability endpoints",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e52afc2-dfc2-4404-9658-9cc2f296d387",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.48,
        "y": 0.6
      },
      "kind": "paragraph",
      "text": "PRIMARY ENDPOINT: Investigator-rated PTSD symptoms on CAPS-5 Total Symptom Severity Scores in change from Baseline to Week 12 compared to placebo",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "efd425b5-e5ce-43fb-bd62-d232032f3930",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.06,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "BID = Twice daily dosing; CAPS-5 = Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e4d598f-f46b-463c-9138-e760aa53227b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.06,
        "y": 0.03
      },
      "kind": "title",
      "text": "BNC210 Phase 2b PTSD ATTUNE Study Underway",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bed3ed90-530f-435a-9704-6ce9a81eda1f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "1278889b-cec5-4438-b3fc-61c4437fc2c8",
      "evidence": "Timeline visualization of clinical trial phases",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}